Press Enter to search · Esc to close
A landmark phase 3 trial puts the dual-receptor agonist on the map for adolescents with type 2 diabetes — and new mechanistic work suggests its effects reach all the way down to the mitochondrion.
Nephrologists are floating a new diagnostic umbrella — Metabolic Kidney Disease — to catch the quiet damage that obesity, insulin resistance and fatty liver inflict on kidneys years before standard tests flag a problem.
The disease formerly known as fatty liver got a new name in 2023 — and a fresh acknowledgment that it rarely travels alone. Here's what the latest review tells us about the liver-kidney link.
The world's most common chronic liver disease just got a new name. The bigger shift: doctors now treat it as a cardiometabolic problem, because most patients die of heart disease, not cirrhosis.
New research links liver fibrosis to clogged arteries — and reframes a condition once filed under 'gastro' as a heart-and-metabolism story parents can't afford to ignore.
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
A three-year cohort of type 2 diabetics tracked who silently progressed to liver fibrosis — and which routine lab markers offered the earliest warning.